Skip to main content
. 2020 Dec 13;12(12):3752. doi: 10.3390/cancers12123752

Table 1.

Registered clinical trials targeting pro-inflammatory cytokines in patients with cancer metastases.

Tested Drug NCT Number Title Status Conditions Phases Enrollment Start Date Completion Date
IL-6 pathway
IL-6
Siltuximab, anti-IL-6 chimeric monoclonal antibody NCT00433446 S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients with Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy Completed Metastatic Prostate Cancer Phase 2 62 2007 2011
NCT00385827 A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects with Metastatic Hormone-Refractory Prostate Cancer (HRPC) Terminated Metastatic Prostate Cancer Phase 2 106 2017 2021
NCT04191421 Siltuximab and Spartalizumab in Patients with Metastatic Pancreatic Cancer Recruiting Metastatic Stage IV Pancreatic Cancer Phase 1|Phase 2 42 2020 2022
Tocilizumab, humanized monoclonal antibody against IL-6 receptor NCT03135171 Trastuzumab and Pertuzumab in Combination with Tocilizumab in Subjects with Metastatic HER2-Positive Breast Cancer Resistant to Trastuzumab Recruiting HER2+ Breast Cancer Phase 1 20 2017 2021
JAK
Ruxolitinib, JAK1 and JAK2 inhibitor NCT00638378 Study of Ruxolitinib (INCB018424) Administered Orally to Patients with Androgen-Independent Metastatic Prostate Cancer Terminated Prostate Cancer Phase 2 22 2008 2009
NCT01594216 Ruxolitinib in Estrogen Receptor-Positive Breast Cancer Completed Estrogen Receptor-Positive Invasive Metastatic Breast Cancer Phase 2 29 2012 2016
NCT02120417 A Study of Ruxolitinib in Combination with Capecitabine in Subjects with Advanced or Metastatic HER2-Negative Breast Cancer Terminated Breast Cancer Phase 2 149 2014 2017
NCT02041429 Ruxolitinib W/Preop Chemo for Triple-Negative Inflammatory Breast cancer Active, not recruiting Recurrent Breast Cancer| Metastatic Breast Cancer Phase 1|Phase 2 24 2014 2021
NCT02066532 Ruxolitinib in Combination with Trastuzumab in Metastatic HER2-Positive Breast Cancer Active, not recruiting Metastatic Breast Cancer|HER-2 Positive Breast Cancer Phase 1|Phase 2 28 2014 2020
NCT03012230 Pembrolizumab and Ruxolitinib Phosphate in Treating Patients with Metastatic Stage IV Triple-Negative Breast Cancer Recruiting Metastatic Malignant Neoplasm in the Bone Stage IV Breast Cancer|Triple-Negative Breast Carcinoma Phase 1 18 2017 2021
NCT02876302 Study of Ruxolitinib (INCB018424) With Preoperative Chemotherapy for Triple-Negative Inflammatory Breast Cancer Recruiting Inflammatory Breast Cancer Phase 2 64 2017 2024
Itacitinib, JAK1 inhibitor NCT03670069 Itacitinib in Treating Patients with Refractory Metastatic/Advanced Soft Tissue Sarcomas Recruiting Metastatic Leiomyosarcoma|Metastatic Synovial Sarcoma Phase 1 28 2019 2022
STAT
BBI608, STAT3 inhibitor NCT03522649 A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients with Metastatic Colorectal Cancer Recruiting Previously Treated Metastatic Colorectal Cancer Phase 3 668 2018 2021
NCT03647839 Modulation of The Tumor Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergize With PD1 Inhibition in Microsatellite-Stable, Refractory Colorectal Cancer Patients Active, not recruiting Colorectal Cancer Metastatic Phase 2 90 2018 2022
WP1066, JAK2/STAT3 inhibitor NCT01904123 STAT3 Inhibitor WP1066 in Treating Patients with Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain Recruiting Metastatic Malignant Neoplasm in the Brain| Metastatic Melanoma Phase 1 33 2018 2021
NCT04334863 AflacST1901: Peds WP1066 Recruiting Brain Tumor|Medulloblastoma|BrainMetastases Phase 1 36 2020 2023
IL-1
Canakinumab, human anti-IL-1β monoclonal antibody NCT03631199 Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy with or without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-Squamous and Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects Active, not recruiting Non-Small Cell Lung Cancer Phase 3 673 2018 2022
NCT04581343 A Phase 1B Study of Canakinumab, Spartalizumab, Nab-Paclitaxel, and Gemcitabine in Metastatic PC Patients Recruiting Metastatic Pancreatic Ductal Adenocarcinoma Phase 1 10 2020 2022
Anakinra, human interleukin 1 receptor antagonist NCT00072111 Anakinra in Treating Patients with Metastatic Cancer Expressing the Interleukin-1 Gene Completed Metastatic Cancer Phase 1 2003 2015
NCT02090101 Study Evaluating the Influence of LV5FU2 Bevacizumab Plus Anakinra Association on Metastatic Colorectal Cancer Completed Metastatic Colorectal Cancer Phase 2 32 2014 2017
NCT01802970 Safety and Blood Immune Cell Study of Anakinra Plus Physician’s Chemotherapy Choice in Metastatic Breast Cancer Patients Completed Metastatic Breast Cancer Phase 1 10 2012 2017
NCT01624766 Everolimus and Anakinra or Denosumab in Treating Participants with Relapsed or Refractory Advanced Cancers Active, not recruiting Advanced Malignant Neoplasm|Metastatic Malignant Neoplasm|Recurrent Malignant Neoplasm|Refractory Malignant Neoplasm Phase 1 57 2012 2020
CCL2
Carlumab NCT00992186 A Study of the Safety and Efficacy of Single-Agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants with Metastatic Castrate-Resistant Prostate Cancer Completed Prostate cancer Phase 2 46 2009 2011
CSF
SNDX-6352, CSF receptor inhibitor NCT03238027 A Phase 1 Study to Investigate SNDX-6352 Alone or in Combination With Durvalumab in Patients With Solid Tumors Active, not recruiting Solid Tumor|Metastatic Tumor Phase 1 45 2017 2021
SDF-1
Olaptesed, binding to SDF-1 NCT03168139 Olaptesed (NOX-A12) Alone and in Combination with Pembrolizumab in Colorectal and Pancreatic Cancer Patients Completed Metastatic Colorectal Cancer|Metastatic Pancreatic Cancer Phase 1|Phase 2 20 2017 2020
MIF
Anti-MIF antibody NCT01765790 Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors Completed Metastatic Adenocarcinoma of the Colon or Rectum Phase 1 68 2012 2016